Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

214 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities.
Jiang YZ, Ma D, Jin X, Xiao Y, Yu Y, Shi J, Zhou YF, Fu T, Lin CJ, Dai LJ, Liu CL, Zhao S, Su GH, Hou W, Liu Y, Chen Q, Yang J, Zhang N, Zhang WJ, Liu W, Ge W, Yang WT, You C, Gu Y, Kaklamani V, Bertucci F, Verschraegen C, Daemen A, Shah NM, Wang T, Guo T, Shi L, Perou CM, Zheng Y, Huang W, Shao ZM. Jiang YZ, et al. Among authors: verschraegen c. Nat Cancer. 2024 Apr;5(4):673-690. doi: 10.1038/s43018-024-00725-0. Epub 2024 Feb 12. Nat Cancer. 2024. PMID: 38347143
Clinical markers of immunotherapy outcomes in advanced sarcoma.
Husain M, Quiroga D, Kim HG, Lenobel S, Xu M, Iwenofu H, Chen JL, Verschraegen C, Liebner D, Tinoco G. Husain M, et al. Among authors: verschraegen c. BMC Cancer. 2023 Apr 7;23(1):326. doi: 10.1186/s12885-023-10758-w. BMC Cancer. 2023. PMID: 37029351 Free PMC article.
Emerging Trends in Immunotherapy for Adult Sarcomas.
Husain M, Chen L, Liebner D, Beane J, Rubinstein M, Pollock R, Verschraegen C, Tinoco G. Husain M, et al. Among authors: verschraegen c. Oncologist. 2023 May 8;28(5):e233-e241. doi: 10.1093/oncolo/oyad052. Oncologist. 2023. PMID: 36905579 Free PMC article.
Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
Sukrithan V, Armbruster H, Rogers S, Vogt SM, Grenade C, Verschraegen C, Zhou Y, Goyal A, Natwa M, Hussein A, Barr H, Konate D, Batdorf R, Brown A, Williams B, Zhao S, Wei L, Xu M, Shah MH, Konda B. Sukrithan V, et al. Among authors: verschraegen c. PLoS One. 2024 May 15;19(5):e0298824. doi: 10.1371/journal.pone.0298824. eCollection 2024. PLoS One. 2024. PMID: 38748739 Free PMC article.
Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review.
Patel S, Armbruster H, Pardo G, Archambeau B, Kim NH, Jeter J, Wu R, Kendra K, Contreras CM, Spaccarelli N, Dulmage B, Pootrakul L, Carr DR, Verschraegen C. Patel S, et al. Among authors: verschraegen c. PLoS One. 2024 Apr 30;19(4):e0297531. doi: 10.1371/journal.pone.0297531. eCollection 2024. PLoS One. 2024. PMID: 38687774 Free PMC article.
Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma.
Kwok C, Khorasanchi A, Psutka SP, Hinkley M, Dason S, Sundi D, Yang Y, Yang Y, Verschraegen C, Gross EE, Orcutt D, Yin M. Kwok C, et al. Among authors: verschraegen c. Front Oncol. 2023 Jul 27;13:1231831. doi: 10.3389/fonc.2023.1231831. eCollection 2023. Front Oncol. 2023. PMID: 37576889 Free PMC article.
214 results